Modak Mrinalini, Rowlands Wiktoria M, Sleiman Joelle, Attaway Amy H, Bleecker Eugene R, Zein Joe
Department of Medicine, University of Oklahoma, Health Sciences Center, Oklahoma City, Oklahoma, United States.
Department of Medicine, Staten Island University Hospital, Staten Island, New York, United States.
Chronic Obstr Pulm Dis. 2025 Jul 30;12(4):260-273. doi: 10.15326/jcopdf.2024.0566.
Chronic obstructive pulmonary disease (COPD) and asthma account for a significant health care burden within the United States. The asthma-COPD overlap (ACO) phenotype has been associated with increased exacerbation frequency and health care utilization compared to either disease alone. However, hospital-based outcomes of these diagnoses have not been described in the literature.
Hospitalization data were extracted from the Healthcare Cost and Utilization Project Nationwide Readmissions Database (HCUP-NRD 2012-2015). Using International Classification of Diseases, Ninth Revision, Clinical Modification codes, we classified patients as having asthma, COPD, or ACO. We used analytic sample weights to compute national estimates, and weighted regression analyses to evaluate hospitalization outcomes.
Of 2,522,013 patients reviewed, 1,732,946 (68.7%) had COPD, 668,867 (26.5%) had asthma, and 120,200 (4.8%) had ACO. Patients with ACO were younger than those with COPD (63 versus 69 years old, < 0.05), with a higher rate of respiratory failure and an increased hospital length of stay. Index admission mortality was higher in patients with COPD (adjusted odds ratios [OR] [95%]: 2.10 [1.84; 2.40]) and asthma (adjusted OR [95%]: 1.59 [1.38; 1.83]) as compared to those with ACO. However, the all-cause readmission rate was higher in the COPD group (15.7%) but not in the asthma group (10.7%) as compared to the ACO group (11.5%).
While ACO was associated with higher rates of baseline comorbidities, increased length of stay, and higher health care cost during index admission, this did not translate into higher in-hospital mortality, complication rates, or risk for asthma-related readmission mortality when compared to asthma or COPD alone, highlighting the complexity of the ACO disease burden.
慢性阻塞性肺疾病(COPD)和哮喘给美国的医疗保健带来了沉重负担。与单独的任何一种疾病相比,哮喘-慢性阻塞性肺疾病重叠综合征(ACO)表型与更高的急性加重频率和医疗保健利用率相关。然而,这些诊断在医院的治疗结果在文献中尚未得到描述。
从医疗保健成本与利用项目全国再入院数据库(2012 - 2015年HCUP - NRD)中提取住院数据。使用国际疾病分类第九版临床修订本编码,我们将患者分类为患有哮喘、COPD或ACO。我们使用分析样本权重来计算全国估计数,并使用加权回归分析来评估住院治疗结果。
在审查的2,522,013名患者中,1,732,946名(68.7%)患有COPD,668,867名(26.5%)患有哮喘,120,200名(4.8%)患有ACO。ACO患者比COPD患者年轻(63岁对69岁,<0.05),呼吸衰竭发生率更高,住院时间更长。与ACO患者相比,COPD患者(调整后的比值比[OR][95%]:2.10[1.84;2.40])和哮喘患者(调整后的OR[95%]:1.59[1.38;1.83])的首次入院死亡率更高。然而,与ACO组(11.5%)相比,COPD组的全因再入院率更高(15.7%),而哮喘组(10.7%)则不然。
虽然ACO与更高的基线合并症发生率、更长的住院时间以及首次入院期间更高的医疗保健成本相关,但与单独的哮喘或COPD相比,这并未转化为更高的住院死亡率、并发症发生率或哮喘相关再入院死亡率风险,这凸显了ACO疾病负担的复杂性。